Discontinuation of Denosumab and Associated Fracture Incidence: Analysis From the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

Osteoporosis is a chronic disease and requires long-term treatment with pharmacologic therapy to ensure sustained antifracture benefit. Denosumab reduced the risk for new vertebral, nonvertebral, and hip fractures over 36 months in the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Brown, Jacques P, Roux, Christian, Törring, Ove, Ho, Pei-Ran, Beck Jensen, Jens-Erik, Gilchrist, Nigel, Recknor, Christopher, Austin, Matt, Wang, Andrea, Grauer, Andreas, Wagman, Rachel B
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Subscription Services, Inc., A Wiley Company 2013
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3617467/
https://ncbi.nlm.nih.gov/pubmed/23109251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jbmr.1808
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados